Altogether, our findings suggest that both synovial Axl and MerTK are influenced by exposure to treatment and linked to synovial pathology; we also propose a regulatory mechanism for Axl synovial expression in RA driven by IL-6 receptor inhibition therapy in vivo. Here, AXL is linked to rheumatoid arthritis.